Hadassah

Israeli Biotech Co. Receives Major Grant to Further Develop Treatment for AMD

Wednesday, May 13 2015

To further develop its world-first, animal product-free stem cell treatment for age-related macular degeneration (AMD), Israel’s Cell Cure Neurosciences Ltd. has received a 6.24 million shekel (approximately $1.6 million dollar) grant from Israel's Office of the Chief Scientist (OCS).

A clinical trial using this product was initiated in February at the Hadassah Medical Organization, whose Prof. Benjamin Reubinoff, Chief Scientific Officer of Cell Cure and Director of Hadassah's Human Embryonic Stem Cell Research Center, and Prof. Eyal Banin, head of the Center for Retinal and Macular Degeneration, were instrumental in its development. The product, called OpRegen®, is a retinal pigment epithelial (RPE) cell formulation derived from human embryonic stem cells (hESCs), characterized by high purity and potency.

"We thank the Israel Office of the Chief Scientist for its commitment to innovation and for continuing support of Cell Cure and its development of a cell therapy-based treatment for a major disease of aging," said Charles Irving, PhD, Chief Executive Officer of Cell Cure.

"I join with Dr. Irving in thanking the OCS for its generous support in advancing pluripotent stem cell research into clinical applications," Prof. Reubinoff related.

The Phase I/IIa study of OpRegen® has been designed to provide preliminary, objective, functional and structural data on this cell transplantation's ability to slow the progression of geographic atrophy (dry-AMD), in addition to safety data. Dry-AMD severely impacts the quality of life of the elderly and there is as yet no approved therapy.

The clinical trial, involving four groups of patients, will evaluate three different dose regimens. Cell Cure expects to report interim data from the cohorts in the coming months. Details of the trial are available at https://clinicaltrials.gov/ct2/show/NCT02286089?term=OpRegen&rank=1

Dry AMD is the leading cause of visual impairment and blindness among the elderly in the US and other developed countries. While treatment options exist for the treatment of the wet form of AMD, 90 percent of all patients with AMD have the dry form. As Cell Cure's website explains: "The root cause of dry-AMD is believed to be the dysfunction of RPE cells. Therefore, one of the most exciting new therapeutic strategies for dry-AMD is the transplantation of healthy young RPE cells to support and replace those lost with age. Pluripotent stem cells, such as hESCs, can potentially provide a means of manufacturing such healthy RPE cells on an industrial scale."

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Sep 21 2018

Hadassah Numbers to Commend and Celebrate

Over the past year, Hadassah Medical Center researchers received over 60 percent of the National Science Foundation Awards for biomedical research in Israeli hospitals...

READ MORE ›
alt_text

Thursday, Sep 20 2018

NanoKnife® Technology to Treat Prostate Cancer Comes to Hadassah

NanoKnife® technology, the most innovative method for treatment of localized prostate cancer, is now being applied at the Hadassah Medical Organization, making Hadassah the first in Israel to treat prostate cancer in this minimally invasive way.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Car-ramming Victim and His Family Give Thanks

Life in the Horaling family changed forever on November 17, 2017. Dad Ebenezer Horaling, 35, was taking a bus to work as a custodian at a boys’ junior high school 20 minutes away from his home. Ebenezer had gotten off the bus and was walking to the school when a 17-year-old terrorist drove into him, throwing him into the air.

READ MORE ›
alt_text

Thursday, Sep 20 2018

Hadassah Director General Organizes Surprise for Hospitalized Children

Providing a respite from medical treatment during this holiday season, a collection of antique cars suddenly appeared on the lawns of Hadassah Hospital Ein Kerem, and the hospitalized children and their families were invited to take a close look.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More